Antimicrobial Peptides Targeting Intracellular Bacteria

Back to all technologies
Download as PDF
2019-CHMI-68405
Researchers at Purdue University developed antimicrobial agents against intracellular human pathogens with improved efficacy compared to the group's previous-generation compounds. Drug resistant bacteria are an increasing worldwide threat, especially in the healthcare environment. Compounding the threat, many bacterial species localize within human cells. Designing and formulating drugs to reach inside host cells without damaging those cells is a key challenge in treating bacterial infection. The Purdue team employs cell-penetrating peptides to meet this challenge. Their newest generation of peptide-based compounds compares well to vancomycin and gentamicin, in some cases outperforming the established antibiotics in cell culture. The Purdue peptides also demonstrate excellent cell penetrating ability and safety against human cells.

Advantages:
-Penetrates human cells to target intracellular pathogens
-Effective alone or as a covalent conjugate with other antibiotics
-Avoids use of delivery vehicles

Potential Applications:
-Antibiotic therapeutic
-Pharmaceuticals

Technology is validated: In vitro testing (patent)
Nov 13, 2019
Utility Patent
United States
10,875,895
Dec 29, 2020

Nov 12, 2019
PCT-Patent
WO
(None)
(None)

Oct 16, 2019
Provisional-Patent
United States
(None)
(None)

Dec 4, 2018
Provisional-Patent
United States
(None)
(None)
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org